Literature DB >> 10768628

Autoantibodies in thymoma-associated myasthenia gravis with myositis or neuromyotonia.

A Mygland1, A Vincent, J Newsom-Davis, H Kaminski, F Zorzato, M Agius, N E Gilhus, J A Aarli.   

Abstract

BACKGROUND: About 50% of patients with thymoma have paraneoplastic myasthenia gravis (MG). Myositis and myocarditis or neuromyotonia (NMT) will also develop in some. Patients with thymoma-associated MG produce autoantibodies to a variety of neuromuscular antigens, particularly acetylcholine receptor (AChR), titin, skeletal muscle calcium release channel (ryanodine receptor [RyR]), and voltage-gated potassium channels (VGKC).
OBJECTIVE: To examine whether neuromuscular autoantibodies in patients with thymoma correlate with specific clinical syndromes.
METHODS: Serum and plasma samples from 19 patients with thymoma-associated MG, of whom 5 had myositis and 6 had NMT, underwent testing for antibodies to AChR, titin, RyR, and VGKC.
RESULTS: Antibodies to AChR and titin were found in 19 and 17 patients, respectively. Antibodies to RyR correlated with the presence of myositis (P = .03); they were found in all 5 patients with myositis and in only 1 patient with NMT, but also in 4 of 8 patients with neither disease. Antibodies to VGKC were found in 4 patients with NMT, 1 of 3 patients undergoing testing for myositis, and 2 of 7 patients undergoing testing with neither comorbidity. Presence of RyR antibodies correlated with high levels of titin antibodies.
CONCLUSIONS: The results appear to distinguish partially between 3 groups of patients with thymoma-associated MG: the first with RyR antibodies and myositis or myocarditis, the second with NMT without RyR antibodies, and the third without RyR antibodies, myositis, or NMT. Differences in the thymoma may underlie these pathologic associations.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10768628     DOI: 10.1001/archneur.57.4.527

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  13 in total

1.  Effect of complement and its regulation on myasthenia gravis pathogenesis.

Authors:  Linda L Kusner; Henry J Kaminski; Jindrich Soltys
Journal:  Expert Rev Clin Immunol       Date:  2008-01       Impact factor: 4.473

Review 2.  Perioperative management in myasthenia gravis: republication of a systematic review and a proposal by the guideline committee of the Japanese Association for Chest Surgery 2014.

Authors:  Yoshihisa Kadota; Hirotoshi Horio; Takeshi Mori; Noriyoshi Sawabata; Taichiro Goto; Shin-ichi Yamashita; Takeshi Nagayasu; Akinori Iwasaki
Journal:  Gen Thorac Cardiovasc Surg       Date:  2015-01-22

Review 3.  Thymoma and autoimmunity.

Authors:  Shahar Shelly; Nancy Agmon-Levin; Arie Altman; Yehuda Shoenfeld
Journal:  Cell Mol Immunol       Date:  2011-02-14       Impact factor: 11.530

Review 4.  Muscle autoantibodies in myasthenia gravis: beyond diagnosis?

Authors:  Matthew N Meriggioli; Donald B Sanders
Journal:  Expert Rev Clin Immunol       Date:  2012-07       Impact factor: 4.473

Review 5.  Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity.

Authors:  Matthew N Meriggioli; Donald B Sanders
Journal:  Lancet Neurol       Date:  2009-05       Impact factor: 44.182

6.  [Polymyositis associated with thymoma].

Authors:  B Jordan; K Eger; S Zierz
Journal:  Nervenarzt       Date:  2009-06       Impact factor: 1.214

7.  Three types of striational antibodies in myasthenia gravis.

Authors:  Shigeaki Suzuki; Kimiaki Utsugisawa; Yuriko Nagane; Norihiro Suzuki
Journal:  Autoimmune Dis       Date:  2011-07-17

8.  Two simultaneous autoimmune processes in a patient presenting with respiratory insufficiency.

Authors:  Lauren Troy; Paul Hamor; Jane Bleasel; Tamera Corte
Journal:  Respirol Case Rep       Date:  2013-12-20

9.  A case of late-onset, thymoma-associated myasthenia gravis with ryanodine receptor and titin antibodies and concomitant granulomatous myositis.

Authors:  M I Stefanou; L Komorowski; S Kade; A Bornemann; U Ziemann; M Synofzik
Journal:  BMC Neurol       Date:  2016-09-13       Impact factor: 2.474

Review 10.  [Chemotherapy definitions and policies for thymic malignancies].

Authors:  Nicolas Girard; Rohit Lal; Heather Wakelee; Gregory J Riely; Patrick J Loehrer
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2014-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.